Press and Publications

CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs

Recida’s new LpxC inhibitor is a potential treatment for multidrug-resistant Enterobacteriaceae and P. aeruginosa infections (BOSTON, MA) – February 06, 2019 – CARB-X, a Boston University global partnership, is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to...

Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant Infections

Novel-class LpxC inhibitor licensed from FUJIFILM Toyama Chemical Co. Ltd.  $8.5M Series A financing led by Frazier  $4.4M awarded from CARB-X  Greater China rights partnered with MicuRx Pharmaceuticals, Inc. Menlo Park, Calif., February 6, 2019 – Frazier Healthcare Partners today announced the launch of Recida Therapeutics, Inc., a biopharmaceutical company...